Clovis Oncology’s (CLVS) Buy Rating Reaffirmed at Stifel Nicolaus
Stifel Nicolaus reiterated their buy rating on shares of Clovis Oncology Inc. (NASDAQ:CLVS) in a research note published on Monday morning. They currently have a $45.00 target price on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the company. Piper Jaffray Cos. set a $14.00 price objective on Clovis Oncology and gave the company a hold rating in a report on Thursday, August 18th. JPMorgan Chase & Co. reissued a hold rating and issued a $13.00 price objective on shares of Clovis Oncology in a report on Tuesday, August 9th. Zacks Investment Research raised Clovis Oncology from a hold rating to a buy rating and set a $18.00 price objective on the stock in a report on Thursday, August 11th. SunTrust Banks Inc. began coverage on Clovis Oncology in a report on Friday, August 5th. They issued a buy rating and a $25.00 price objective on the stock. Finally, Credit Suisse Group AG reissued a hold rating on shares of Clovis Oncology in a report on Tuesday, July 12th. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $36.39.
Clovis Oncology (NASDAQ:CLVS) traded up 2.35% on Monday, hitting $32.60. The stock had a trading volume of 102,323 shares. The company’s 50 day moving average is $31.36 and its 200-day moving average is $19.25. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $109.18. The stock’s market cap is $1.26 billion.
Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.13) by $0.06. During the same period last year, the business earned ($2.10) EPS. Analysts forecast that Clovis Oncology will post ($9.25) EPS for the current year.
Institutional investors have recently modified their holdings of the company. Parametric Portfolio Associates LLC acquired a new position in shares of Clovis Oncology during the second quarter worth about $144,000. Fox Run Management L.L.C. purchased a new position in Clovis Oncology during the second quarter valued at $154,000. Creative Planning increased its position in Clovis Oncology by 524.4% in the third quarter. Creative Planning now owns 11,638 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 9,774 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in Clovis Oncology during the first quarter valued at $233,000. Finally, Kazazian Asset Management LLC purchased a new position in Clovis Oncology during the first quarter valued at $282,000. Institutional investors own 98.50% of the company’s stock.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.